The focus of the industry is living organisms. The highly regulated www.genotec-frankfurt.de/top-5-simple-virtual-deal-software-for-beginners/ standards make it a unique consideration for business leaders. These aspects make the sector an ideal place to foster innovation. They have led to major breakthroughs in the production of biofuels and agricultural yields and life-saving pharmaceuticals.

When you think of strategies to generate revenue biotech start-ups have a myriad of options. The majority of them choose a technology partnership or an asset creation-and-out-licensing strategy. Technology partnering can bring faster revenue and lower financial risk, while asset creation and outlicensing strategies can yield significantly more returns. An increasing number of research-stage biotechs operate an hybrid model that blends both approaches.

Those who choose a product-oriented strategy can reap commercial success in the event that they manage to bring their pipelines up to the right place, and attract a large pharmaceutical partner or investor with a deep pocket. This is costly, however, and managing opportunistic approaches to leverage outside resources with the right scientific decisions about homegrown projects is essential.

The “platform” model is another alternative to generate revenue. It’s a less costly option than the product-oriented development however, it comes with substantial risk. In this model biotechs have the ability to develop their own platform technology, before teaming with pharma companies to create a range of drug discovery projects aimed at specific diseases (i.e. disease of x in biology). This is the method Advinus Therapeutics and a few others have followed.